Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsuniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]
Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.
Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.
ACR Convergence 2025 Recap: Late-Breaking Trials to Know
Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial
1.
Distribution of fat could influence cancer risk, study suggests
2.
Study looks into cancer-related harmful communication.
3.
Q&A: When will individuals be able to receive customized cancer vaccines?
4.
Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness
5.
An Eye Surgeon's Unexpected Discovery of the "Before and After".
1.
Lymphomatoid Papulosis: What You Need to Know
2.
Understanding Hemosiderosis: Causes, Symptoms, and Treatment Options
3.
Omitting Axillary Dissection in Node-Positive Breast Cancer: Insights from the SENOMAC Trial
4.
Preventing Heparin Induced Thrombocytopenia: Tips for Successful Anticoagulation Therapy
5.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
3.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
4.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
5.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge